Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Neurogenic pain is defined as pain due to dysfunction of the peripheral or central nervous system, in the absence of nociceptor (nerve terminal) stimulation by trauma or disease. Other terms used to describe some (but not all) forms of neurogenic pain include neuropathic pain, deafferentation pain, and central pain; all these terms are subsumed into the wider expression 'neurogenic pain'. The clinical syndromes representing this type of disorder make up at least 25% of the patients attending most pain clinics. This is undoubtedly proportionately greater than its incidence in chronic pain as a whole, and is a measure of its intractability and of the therapeutic dilemma which it presents. However, neurogenic pain syndromes are much commoner than is perhaps generally recognized: when all categories are taken into account, there are probably more than 550,000 cases in the UK population of 56 million at any one time, i.e. a prevalence of about 1%.
 ...
PMID:Neurogenic pain syndromes and their management. 179 77

The reliability of distinguishing central, musculoskeletal, and syringomyelic pain by two points of history: (1) pain quality and (2) pain location relative to the level of paralysis in spinal cord injury patients was tested by (1) physical examination, and (2) by radiographic imaging. Fifty five incidents of chronic pain (median duration 10 years, range 3 weeks-42 years) were found in a survey of 66 spinal cord injured patients. Central pain was suggested in 24 patients on the basis of a predominant 'neurogenic' pain quality: burning, stabbing, needles and pins, or numbness; and a location at or distal to the level of paralysis. Neurogenic pain was not associated with structural pathology in these patients. Musculoskeletal pain was suggested in 20 instances on the basis of predominantly aching pain and a location at or distal to the level of paralysis. Aching pain was associated with degenerative joint disease (11 each); scoliosis, shoulder dislocation, contractures (2 each); fracture, soft tissue calcium deposit (1 each) in 19 patients. Syringomyelic pain was suggested in 11 instances solely on the basis of pain location above the level of paralysis. Magnetic resonance imaging revealed extensive syringomyelia in 8 patients. It is proposed that the quality and location of chronic pain can quickly suggest confirmatory examinations, sometimes revealing correctable causes.
 ...
PMID:Chronic pain after spinal cord injury: an expedient diagnostic approach. 225 Sep 89

Neurogenic pain is by definition linked to a lesion of the pain pathways at any level. There are many causes for the neurological pain which can be present in sympathetic disorders, in peripheral neuropathies and central nervous disorders too. In despite of these multiple aetiologies, the neurological pain is characterised by: demyelinisation at the anatomic lesion; a spontaneous firing described by the authors as related to three mechanisms, sensitivation, deafferentation and lost of inhibition; a common and specific clinical semiology very different indeed from the peripheral pain described as a surafferentation.
 ...
PMID:[Neurological pain]. 780 47

Neurogenic pain (encompassing all types of neuropathic and central pain) is discussed. Experimental work is presented in a model in which the rat sciatic nerve is loosely ligatured. In painful human neuropathies, tricyclic antidepressants have been found to be effective in proportion to the degree they facilitate monoaminergic activity. Several papers also stress the importance of early treatment with amitriptyline or desipramine, and the ineffectiveness of analgesics, including narcotics. In nociceptive pain, recent findings in humans emphasize the importance of both the retroinsular (SII) and the anterior cingulate cortices in the conscious appreciation of pain. Opioid studies have revealed individual differences in the metabolism of morphine to its 3- and 6-glucuronosides; patients with nociceptive pain who respond poorly to morphine or diamorphine probably have a high 3:6 ratio. It has been pointed out that methadone may be useful in such cases, as it is not broken down to glucuronosides.
 ...
PMID:Pain syndromes and their treatment. 809 40

Seventeen patients with severe disabling spinal spasticity were selected and treated by chronic intrathecal baclofen infusion using an implanted programmable pump. Nine patients were tetraparetic, seven were paraplegic and one paraparetic. Patients were regularly followed for 5 to 69 months (mean 37.5 months). The clinical efficacy of baclofen was estimated by means of evaluation of: hypertonia, spasms, pain and functional disability. All patients experienced significant amelioration of quality of life secondary to reduction of hypertonia, spasms and pain related to contractures. Neurogenic pain improved in 3 cases and remained unchanged in 3 others. In patients whose motor functions were partially preserved, various degrees of motor improvement were detected. Electrophysiological recordings of Polysynaptic flexion reflexes (FR) were obtained to control conditions, and under intrathecal baclofen, in order to quantify the spinal excitability responsible for spontaneous or induced spasms. Flexion reflex threshold was increased and amplitude proved to be very significantly reduced by chronic baclofen infusion in all our patients. Twelve patients with neurogenic bladder dysfunction were also evaluated by a clinically oriented questionnaire and by quantitative urodynamic recordings, before and after pump implantation. In patients with normal micturition, this was not changed by intrathecal baclofen. In patients with spastic bladder, intrathecal baclofen produced a decrease of detrusor hypertonia and hyperactivity in 50% of cases, with reduction of leakage and increase in functional bladder capacity.
 ...
PMID:Long-term clinical, electrophysiological and urodynamic effects of chronic intrathecal baclofen infusion for treatment of spinal spasticity. 874 77

Pain is a common complaint following spinal cord injury (SCI). While nociceptive pain can often be effectively managed by traditional therapies, neurogenic pain is more refractory to treatment. Several categories of pain are recognized in persons with SCI and an accurate diagnosis will improve the therapeutic response. Nociceptive pain is usually perceived to be above or at the level of the cord lesion and is most commonly related to musculoskeletal pathology. Neurogenic pain is usually felt by the patient at or below the neurological level and may be classified as radicular, segmental or deafferentation central pain, depending on its hypothetical origin and the clinical presentation. Management requires recognition of all factors that may influence pain perception and knowledge of the entire range of therapeutic options.
 ...
PMID:Management of pain in persons with spinal cord injury. 914 8

FUNDAMENTAL: Analgesia is a fundamental part of management as it helps avoid the morbid effects of pain itself and improves confidence so the child and his parents can accept more easily the diagnosis and proposed treatment. The World Health Organization has established a classification of analgesics. USE OF PLACEBOS: The placebo effect depends on several factors including anxiety, confidence, and the patient's- and prescriber's-expectations and convictions). It is observed early in the first years of childhood. Use of placebos is not recommended as a favorable reaction can be interpreted wrongly, disqualifying the complaint. EFFICACY LEVELS: For level 1, paracetamol has little toxicity and is easily managed for first line use; aspirin and nonsteroid antiinflammatory drugs can also be used if there are no contraindications. Level 2 drugs, codeine or dextropropoxyphene (which is not available in a pediatric formulation) are required for any manifestation of pain not relieved by level 1 drugs. Level 3 corresponds to strong central analgesics, mainly morphine. SPECIFIC PAIN: Antispasmodic agents in combination with paracetamol give partial relief of visceral pain without masking symptoms. Local anesthetics improve comfort without compromising safety. Neurogenic pain does not respond to usual analgesics and can be relieved with tricyclic antidepressors for burning sensations or antiepileptic drugs for fulgurant pain. TREATMENT-RELATED PAIN: Iatrogenic pain, by definition, must be systematically anticipated and prevented.
 ...
PMID:[Analgesics in pediatrics. Drugs for pain relief in children]. 940 61

All patients with cancer invariably experience pain during the course of their disease. Treatment- and diagnosis-related acute pain and persistent pain caused by the disease itself or treatment sequellae are involved. Pain should be suspected, diagnosed and evaluated as a first line symptom. The physician should recognized its different components and pathophysiological mechanisms. Treatment should be prescribed according to the needs of each patient and regularly verified to obtain maximal efficacity with the least side effects. Opiate drugs are frequently used for nocipeptive pain. Neurogenic pain requires selective use of psychotropes.
 ...
PMID:[Pain in cancer patients. Practical attitude]. 929 92

Neurogenic pain is experienced by about 1% of the population. The efficacy of drug treatment for this condition has been poorly evaluated, and only recently have certain treatments been shown to have significant analgesic effects. Monotherapy with topical agents such as capsaicin is not usually sufficient. Oral agents that have proven effective in treating neurogenic pain states include tricyclic antidepressants, selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors and anticonvulsants. Local anaesthetics, administered intravenously, have been reported to relieve pain in selected patients, but data from controlled trials are sparse. Multiple mechanisms contribute to the generation of neurogenic pain. In the future, drug treatment for neurogenic pain is likely to target these mechanisms. Recent studies have shown that N-methyl-D-aspartate (NMDA) receptor antagonists, adenosine receptor agonists and nitric oxide synthase inhibitors may become useful in the treatment of neurogenic pain.
 ...
PMID:How do drugs relieve neurogenic pain? 935 25

The medical treatment and some currently known aspects of the aetiology of five neurogenic pain states are discussed. Neurogenic pain can be described as pain resulting from noninflammatory dysfunction of the peripheral or central nervous system without nociceptor stimulation or trauma. The enormity of the field has limited this review to post-herpetic neuralgia, complex regional pain syndromes, phantom pain, trigeminal neuralgia and diabetic neuralgia. Evidence suggests that many neurogenic pain states are not effectively controlled. This may be due in part to a lack of understanding of the aetiology of these conditions and to the lack of high quality studies evaluating existing treatments. A compact review of the literature is presented with some treatment options and possible future directions. Where appropriate surgical management and physical therapy have been discussed; however, a thorough appraisal of nondrug treatments was not the main priority of this review.
 ...
PMID:Chronic neuropathic pain and its control by drugs. 936 78


1 2 Next >>